EP3669890A1 - Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin - Google Patents

Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin Download PDF

Info

Publication number
EP3669890A1
EP3669890A1 EP18213540.0A EP18213540A EP3669890A1 EP 3669890 A1 EP3669890 A1 EP 3669890A1 EP 18213540 A EP18213540 A EP 18213540A EP 3669890 A1 EP3669890 A1 EP 3669890A1
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
nanoquil
cholesterol
saponin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18213540.0A
Other languages
German (de)
English (en)
Inventor
Kefei Hu
Laurent Duroux
Erik Lindblad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Croda International PLC
Original Assignee
Croda International PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croda International PLC filed Critical Croda International PLC
Priority to EP18213540.0A priority Critical patent/EP3669890A1/fr
Priority to TW108145097A priority patent/TW202038905A/zh
Priority to EP19817767.7A priority patent/EP3897713A1/fr
Priority to AU2019409474A priority patent/AU2019409474A1/en
Priority to JP2021534730A priority patent/JP2022514276A/ja
Priority to BR112021011609-5A priority patent/BR112021011609A2/pt
Priority to CA3123475A priority patent/CA3123475A1/fr
Priority to CN201980083532.7A priority patent/CN113365657A/zh
Priority to US17/312,796 priority patent/US20230321227A1/en
Priority to KR1020217022094A priority patent/KR20210105389A/ko
Priority to PCT/EP2019/085444 priority patent/WO2020127115A1/fr
Priority to ARP190103707A priority patent/AR117712A1/es
Publication of EP3669890A1 publication Critical patent/EP3669890A1/fr
Priority to ZA2021/03649A priority patent/ZA202103649B/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Definitions

  • the present invention relates to filamentous or thread-like nanoparticles comprising sterol and a triterpenoid saponin, such as a component derived from Quillaja saponaria Molina selected from quillaja saponins. More particularly, the invention relates to the use of said filamentous nanoparticles in vaccines, cancer therapy and drug delivery, methods for their production and uses thereof, such as for both human and veterinary use as a vaccine adjuvant.
  • Vaccines require optimal adjuvants including immunopotentiator and delivery systems to offer long term protection from infectious diseases in animals and man.
  • Oil emulsions, lipopolysaccharides, polymers, saponins, liposomes, cytokines, immuno-stimulating complexes (ISCOMs), Freund's complete adjuvant, Freund's incomplete adjuvant, alums, bacterial toxins etc. are common adjuvants under investigation or already implemented in licensed vaccines.
  • Saponin based adjuvants have the ability to stimulate the cell mediated immune system as well as to enhance antibody production and have the advantage that only a low dose is needed for adjuvant activity.
  • ISCOM-matrices are a series of structurally defined sphero ⁇ dal, hollow, cage-like self-assembled nanoparticles (40-60 nm, as observed with Dynamic Light Scattering (DLS)) resulting from the interaction between Quillaja saponins and cholesterol, in a system also containing phospholipids. They exhibit a negative electrostatic charge with a measured ⁇ -potential of about -30 mV.
  • the combination of an ISCOM-matrix with an antigen is called ISCOM. It is believed that Quillaja saponins (and possibly all saponins with a triterpenoid core) possess a high affinity for cholesterol which induces structuration and stabilization of the ISCOM-matrix.
  • ISCOMs have been widely explored for antigen delivery as it mimics a virus particle in terms of size and shape (Barr, 1998).
  • ISCOMs high immune response is mainly associated with the presence of QS ( Quillaja saponaria ) saponins, in particular the acylated components such as QS-21, which exhibit strong immunostimulatory activity (Boyaka et al., 2001).
  • QS Quillaja saponaria
  • QS-21 acylated components
  • This in combination with the particular nature of ISCOMs gives the overall adjuvant effect, and have been reported to induce both humoral and cellular immune responses (Sun et al., 2009).
  • the analytical techniques differ significantly in their methodology and in their pre-analysis sample preparation.
  • TEM a few microliters of the colloidal solution (in phosphate saline buffer, PBS) is deposited onto a metallic grid and dried under vacuum before being sputtered with a contrast agent and visualized with the electron beam. Regions of high electronic density (high molecular density) are observed as projection in a 2D plane.
  • AFM a few microliters of sample are deposited onto an atomically flat substrate (freshly cleaved mica sheet), dried and scanned with a resonant AFM tip only a few nanometers thick. The resulting image gives a topology of the surface of the substrate and where the particles on the surface appear in 3D.
  • the thickness of the particles can be measured.
  • DLS the sample is analyzed as such (i.e. without drying), dissolved in a phosphate buffer, and a statistical description of the particle size distribution is given.
  • AFM imaging the "G3" particles appeared as an heterogenous population of different sizes and shapes, sometimes spheroidal, sometimes elongated along one axis (worm-like) with sizes up to several 100s of nm long, and only a 4 nm to 10 nm thick, never uniformly spherical with a regular diameter between 20 nm and 30 nm.
  • the inventors of the present invention decided to investigate the nature and/or morphology of the "G3 particles" described in WO2013051994 and WO2014163558 closer, since the preparations had after all demonstrated biological effects i.a. in different inoculation experiments.
  • the original procedure as disclosed in WO2013051994 was carried out 5 times and the resulting particles analyzed by DLS.
  • the result was that the original procedure afforded particles having a heterogenous particle size distribution for the individual experiment (see figure 2 ) and further a large variability between the experiments. It was concluded that this lack of homogeneity was unacceptable for a commercial adjuvant.
  • the inventors of the present invention have now found that both the morphology and the size distribution of the particles obtained by the original manufacturing procedure as disclosed in WO2013051994 , can be drastically modified by changing a few critical reaction parameters; in particular by incubating the particles at an elevated temperature and adjusting the ratio between saponin and cholesterol in the initial preparation.
  • particles depicted in the DLS graph of figure 2 which shows two or more types of particles of different apparent sizes
  • particles produced according to the method of the present invention have a uniform size when measured by DLS (mono-dispersed, see figure 4 ).
  • nanoparticles comprising cholesterol and a triterpenoid saponin, such as a component from Quillaja saponaria Molina such as Quil A® or components isolated therefrom, such as fractions QS-7, QS-8, QS-17, QS-18 and QS-21, or a component from Quillaja brasiliensis, such as fraction QB-90, characterized in that said nanoparticles are thread-like (filamentous).
  • a triterpenoid saponin such as a component from Quillaja saponaria Molina such as Quil A® or components isolated therefrom, such as fractions QS-7, QS-8, QS-17, QS-18 and QS-21, or a component from Quillaja brasiliensis, such as fraction QB-90
  • these nanoparticles are henceforth referred to throughout the present application as "NanoQuil F70" particles.
  • the present invention provides a method for producing the NanoQuil F70 nanoparticles of the first aspect, compris
  • the invention also regards a pharmaceutical vaccine formulation comprising the NanoQuil F70 particles according to the present invention, especially as an adjuvant, as mentioned above.
  • the invention also relates to a method for treating or preventing a disease caused or complicated by an organism, comprising administering to a subject a pharmaceutical vaccine formulation according to the invention to a person in need thereof.
  • the invention regards a method for treatment of cancers, including solid tumors, comprising administering to a patient in need thereof a pharmaceutically effective amount of NanoQuil F70 nanoparticles or a composition containing them, according to the present invention.
  • the invention also regards NanoQuil F70 nanoparticles, or a composition containing them, for use in the treatment of cancers, comprising administering to a patient in need thereof a pharmaceutically effective amount of NanoQuil F70 nanoparticles or a composition containing them.
  • the NanoQuil F70 nanoparticles, or compositions containing them may be administered parenterally.
  • parenteral includes subcutaneous injections, intravenous, intramuscular, intradermal injection of infusion techniques, electroporation (EP), for needle less injection -jet injection, gene gun, biljector as well as oral, aerosol administrations.
  • the invention also regards a method for assessing the applicability of the method for treatment of cancer according to the invention to an individual patient, comprising
  • a vaccine formulation is a pharmaceutical formulation that is used prophylactically and improves/enhances protective immunity to/against one or more particular diseases.
  • a therapeutic vaccine according to the invention can be used to cure or treat disease when an antigen specific for a component connected to the disease is included in the formulation with the invention or, as is particular for cancer treatment, the antigen is present in the cancer/tumor.
  • a vaccine includes an "antigen” that elicits an immune response in the treated subject and, optionally, a substance added to a vaccine to improve the immune response called an "adjuvant" or "immunostimulator".
  • an "antigen” is thus the active specific part in a vaccine and may be the entire micro-organism, such as virus or bacteria, causing the disease that the vaccine is aimed at improving immunity to. It may also be a part of said micro-organism a subunit, such as a protein (a sub-unit) a part of a protein, a protein either isolated from the pathogenic microorganism or produced by rDNA technique or synthetically produced then often called peptide.
  • a peptide has fewer amino acids than a protein and generally no ordered 3D structural fold.
  • an “adjuvant” is a vaccine constituent that enhances the level and/or the quality of the immune response to the antigen part of the prophylactic or therapeutic vaccine.
  • the inventors have discovered that the observed heterogeneity (when analysed by Dynamic Light Scattering, DLS) of the particles prepared according the procedure of WO2013051994 surprisingly can be overcome by incubating the particles at an elevated temperature and adjusting the ratio between saponin and cholesterol in the initial preparation.
  • Other process parameters such as the surface area and thickness of the cholesterol film and the solvent polarity may also play a role.
  • the morphology of the "NanoQuil F70" particles produced by the procedure according the present disclosure differs from the morphology of the apparent disc-shaped "G-3" particles produced by the procedure disclosed in WO2013051994 , in that the NanoQuil F70 particles according to the present disclosure are filamentous, "thread-like", and can appear either open-shaped, i.e. worm- or noodle-like, or closed-shape/circular (in contrast to the apparent disc-shaped form in WO2013051994 ), see figure 3A and B .
  • the NanoQuil F70 nanoparticles according to the present invention are not formulated with, and do not contain, phospholipids or co-detergents (such as MEGA-10), in contrast to, for example, ISCOM and ISCOM matrix adjuvant formulations.
  • NanoQuil F70 comprising cholesterol and a triterpenoid saponin, such as a component from Quillaja saponaria Molina such as Quil A®, or components isolated therefrom, such as fractions QS-7, QS-8, QS-17, QS-18 and QS-21, or a component from Quillaja brasiliensis, such as fraction QB-90, characterized in that said nanoparticles are thread-like (filamentous).
  • Nanoparticles according to the first aspect have been found by TEM analysis to exist in two separate forms, both having a characteristic thread-like (filamentous) shape.
  • One form is open-ended, i.e. worm- or noodle-like, the other form is closed, and substantially circular.
  • Nanoparticles produced according to the methods described hereinbelow typically contain both forms.
  • NanoQuil F70 nanoparticles may thus comprise two forms:
  • the ratio of Form A : Form B is influenced by the nature of the employed reaction solvent and/or by the pH of the employed reaction solvent, amongst other parameters.
  • said mixture of Form A and Form B has a ratio of from between 20:80 to 45:55, such as 30:70 to 40:60, such as about 35:65.
  • said mixture of Form A and B has a ratio of from between 5:95 to 10:90.
  • the nanoparticles according to the first aspect are substantially composed of just one form, i.e. the nanoparticles contain at least about 95% of either Form A or Form B.
  • the substantially circular nanoparticles of Form A have a radius of between 10-15 nm and the open-ended nanoparticles of Form B have a length of 35-45 nm, both values as measured by TEM.
  • the filament diameter or thickness is between 4-8 nm, preferably 5-7 nm, such as 5.8 ⁇ 0.8 nm.
  • the substantially circular nanoparticles of Form A have a perimeter of between 65 - 120 nm, such as 70 - 80 nm, such as 80 - 90 nm or such as 85-120 nm.
  • the substantially circular nanoparticles of Form A have a perimeter of 75 ⁇ 7 nm.
  • the substantially circular nanoparticles of Form A have a perimeter of 103.5 ⁇ 17 nm.
  • the ratio between quillaja saponin and cholesterol is from 12:1 to 18:1, such as 14:1 to 17:1, preferably 16:1.
  • NanoQuil F70 nanoparticles according to the first aspect of the present invention differ substantially from the prior art, including the so-called "G3" nanoparticles described in WO2013051994 and WO2014163558 , not least by their unique combination of morphology (filamentous/thread-like vs. disc-like) and particle dispersion (uniform vs. non-uniform).
  • Thread-like nanoparticles have attracted considerable interest in the field of drug delivery systems.
  • PISA Polymerization-Induced Self-Assembly
  • a production method for the filamentous (thread-like) NanoQuil F70 particles of the first aspect comprising the following steps:
  • the layer of cholesterol may be prepared and/or deposited on the surface of a water-insoluble porous article which can be brought in contact with the saponin-solution.
  • the layer of cholesterol can practically be prepared or deposited by evaporation of a solution of cholesterol in a suitable organic solvent.
  • the intimate contact between water-insoluble cholesterol and water-soluble saponins can also be achieved in continuous flow microreactors where separate solutions of cholesterol and saponins are mixed at high speed and high turbulence.
  • reaction vessel refers to any kind and size of container, test tube, barrel, flask, jug, bin or receptacle which is suitable for, and compatible with, the unit operations outlined in the process according to the first aspect.
  • a reaction vessel can conveniently be selected from normal laboratory equipment such as test tubes, centrifuge tubes, one- or multi-necked round-bottomed or pear-shaped flasks etc, which are typically produced from glass or suitable, solvent resistant polymers.
  • a reaction vessel for scale-up and production purposes can be selected from pilot-scale and production scale reactors, which can be glass-lined or produced from stainless steel or other alloys.
  • a water-insoluble, porous article any article of suitable size having an open cell structure and a suitable shape, such as a hollow fibre, and made from a suitable, water-insoluble porous material, such as porous glass, aerogels and other inorganic gels, porous alumina, zirconia or silica particles, metal foams and porous polymers.
  • a suitable, water-insoluble porous material such as porous glass, aerogels and other inorganic gels, porous alumina, zirconia or silica particles, metal foams and porous polymers.
  • the removal of solvent from the cholesterol solution conveniently can be performed by evaporation of the solution. This comprises applying a moderate vacuum, optionally with heating, whilst stirring the contents of the reaction vessel. Said stirring can be performed by spinning the reaction vessel or by applying an internal stirrer inside the reaction vessel such as a stirring bar or paddle stirrer.
  • the removal of solvent from the cholesterol solution can be carried out by passing a stream of air, argon or nitrogen into the reaction vessel, optionally whilst stirring the contents therein. Regardless of the method whereby the solvent is removed, said removal effects a deposition of a layer of cholesterol having a varying thickness and roughness on the inside of the reaction vessel and/or the surface of the porous article.
  • NanoQuil F70 nanoparticles were produced using 4 different aqueous reaction media: Distilled water (D.W.), Saline solution (0.85% NaCl in D.W.), Acetate buffer (pH 4.6) and PBS (pH 7.4) according to the above NanoQuil F70 production protocol.
  • NanoQuil F70 formulated in PBS gives the biggest size (about 42nm), followed by NanoQuil F70 formulated in Saline solution (about 35nm).
  • NanoQuil F70 particles formulated in Acetate buffer (pH 4.6) and distilled water give particle sizes of around 25 and 24 nm respectively (see figure 3C ).
  • the hydrodynamic diameter is the diameter of an equivalent hard sphere that diffuses at the same rate as the analyte, i.e. that of a sphere that has the same translational diffusion coefficient as the particle being measured, assuming a hydration layer surrounding the particle. What is therefore measured is the radius of gyration of the particles in solution. This does not give information about the morphology of the particle under "static" conditions; this can however be assessed by TEM.
  • the aqueous reaction medium added under point b) is a buffer, such as an acetate or PBS buffer.
  • the aqueous reaction medium added under point b) is a solution of one or more salts such as saline (0.85% NaCl in distilled water).
  • the aqueous reaction medium added under point b) is salt-free distilled water.
  • the aqueous reaction medium added under point b) is an acetate buffer having a pH of ⁇ 4.6.
  • the manufacturing process for NanoQuil F70 particles is conducted at a pH of between 4-5.
  • the manufacturing process for NanoQuil F70 particles is conducted at a pH of between 5-6.
  • the manufacturing process for NanoQuil F70 particles is conducted at a pH of between 6-7. In another embodiment the manufacturing process for NanoQuil F70 particles is conducted at a pH of between 7-8.
  • addition of Quil A is preferably performed using an aqueous solution of a concentration at around 1 mg/ml. Sufficient amounts of such a solution is added to produce a final ratio of 10:1 to 20:1, preferably a final ratio of 16:1 (w/w) saponins : Cholesterol.
  • Heating of the resulting reaction mixture at point d) of the process according to the second aspect is an essential feature of the present invention, which drastically changes the morphology and particle size distribution of the particles produced vis-à-vis the particles of WO2013051994 , as described above.
  • the resulting reaction mixture at point d) of the process according to the first aspect is heated to 70 °C ⁇ 5 °C for about an hour.
  • heating is an essential feature of the present invention, the exact reaction temperature, period of heating, rate of heating and temperature profile during heating and subsequent cooling, especially when scaling the production method to a new scale, are parameters which all need to be analyzed and optimized. Analyzing and optimizing process parameters are tasks well understood by the skilled artisan, and considered routine tasks to perform, which do not require inventive skills.
  • the final isolation of the NanoQuil F70 particles of the invention includes a purification step. This step is included because the "raw" NanoQuil F70 particles, which result from the process of formulating saponins with cholesterol according to the second aspect of the present invention, are never totally free of residual free saponin micelles, and thus the NanoQuil F70 crude product may contain free saponin micelles in varying amounts from batch to batch.
  • the final purification step reduces the batch-to-batch variability to an acceptable level, which will be discussed in the following.
  • Saponins from Quillaja species such as QuilA - a commercial mixture of partially purified saponins from Quillaja saponaria Molina - have an inherent lytic activity on biological membranes when delivered as micelles in aqueous buffers, as many other saponins ( Kensil, C. R. et al. (1991). Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. The Journal of Immunology, 146(2), 431-437 ; Oda, K., et al. (2000). Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biological Chemistry, 381(1), 67-74 ). In this form, Quillaja saponins induce an adverse acute inflammation syndrome when injected as vaccine adjuvants, due to its potent cell-membrane lytic effect (a reaction that leads to the disruption or lysis of a cell).
  • the structure of the saponin molecules, possessing both hydrophilic and lipophilic moieties provides these molecules with a pronounced detergent effect.
  • the saponin molecules as such interact with cholesterol and phospholipids on cell membranes, thereby acting as a detergent. This effect is quantified in the hemolysis assay carried out on sheep red blood cells, as described in the Experimental section hereinbelow.
  • NanoQuil F-70 When preparing the NanoQuil F-70, as well as other saponin-containing particulate adjuvants, there may be a certain excess of free saponin that is not immobilized by incorporation into, in this case, the NanoQuil F70 complex with cholesterol.
  • SEC size exclusion chromatography
  • Gel filtration also referred to as size exclusion chromatography, SEC
  • SEC size exclusion chromatography
  • the removal of residual saponin is carried out using, for example, Sephacryl 300 or another gel filtration medium which the skilled artisan will be able to choose without inventive efforts.
  • the SEC methodology is capable of separating the NanoQuil F70 particles with an average size of 20-50 nm (hydrodynamic diameter dependent on reaction medium) from the residual saponin micelles having an average size of ⁇ 5 nm and thereby obtain a product with a highly reduced lytic effect.
  • the hemolytic effect of the analysed nanoQuil F70 nanoparticles is most efficiently presented as "QuilA equivalents".
  • unpurified (raw) nanoQuil F70 induces a hemolytic effect at an equivalent QuilA concentration of 1 mg/mL.
  • the hemolytic effect is similar to that of 0.2 mg/mL free QuilA.
  • the hemolytic effect of this preparation can be therefore deemed about 10x reduced vis-à-vis QuilA itself.
  • Sephacryl 300-HR purified nanoQuil F70 does not show any hemolytic effect until an equivalent QuilA concentration of 2 mg/mL.
  • purified nanoQuil F70 displays a hemolytic effect which is lower or similar to that induced by 0.1 mg/mL free QuilA or 1 mg/mL unpurified nanoQuil F70.
  • the hemolytic effect of the purified nanoQuil F70 nanoparticles can thus be deemed at least 40x reduced vis-à-vis QuilA itself, or about 4x reduced vis-à-vis the raw nanoQuil F70.
  • the hemolytic effect induced by the saponin-containing nanoQuil F70 nanoparticles is reduced at least 20x, such as 20x, 30x or 40x as compared with the hemolytic effect induced by the same saponin, such as QuilA, in pure, uncomplexed form by means of gel filtration techniques such as size exclusion chromatography (SEC) performed on the raw, or crude nanoQuil F70 nanoparticles.
  • SEC size exclusion chromatography
  • the nanoparticles according to the first aspect of the invention are obtainable by the method according to the second aspect.
  • the nanoQuil F70 nanoparticles according to the invention may also be used as delivery systems for one or several compounds e.g. for pharmaceuticals including those used for treatment of cancer and nutrition related compounds where the additional substance(s) provide additional functions and complementary modes of action.
  • the NanoQuil F70 nanoparticles and compositions comprising them may be used as such as a pharmaceutical, optionally in a pharmaceutical composition further comprising pharmaceutically acceptable buffers, diluents excipients, additives, adjuvants and/or carriers.
  • Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art, and it is described, by way of example, in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, USA . Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • the invention also comprises a pharmaceutical composition further comprising at least one pharmaceutically active compound, such as anticancer drugs, platinum coordination compounds, taxane compounds, camptothecin compounds, anti-tumour vinca alkaloids, anti-tumour nucleoside derivatives, nitrogen mustard or nitrosourea alkylating agents, anti-tumour anthracycline derivatives, trastzumab and anti-tumour podophyllotoxin derivatives, Quillaja saponaria Molina and sub fragments thereof, receptors for antibodies or monoclonal antibodies such as Fc receptors or the DD of Protein A of Staphylococcus aureus , agents for treating cancer, such as agents selected from the group consisting of Cytarabin, Daunorubicin, Paclitaxel, Docetaxel, Cabazitaxel, Toricsel and Trabectidin, which active compound may be integrated into the nanoparticle or mixed with the composition.
  • a pharmaceutically active compound such as anticancer drugs,
  • the further anti-cancer agents are preferably selected from platinum coordination compounds, taxane compounds, camptothecin compounds, anti-tumour vinca alkaloids, anti-tumour nucleoside derivatives, nitrogen mustard or nitrosourea alkylating agents, anti-tumour anthracycline derivatives, trastzumab and anti-tumour podophyllotoxin derivatives.
  • platinum coordination compound is used herein to denote any tumour cell growth inhibiting platinum coordination compound which provides platinum in the form of an ion.
  • Preferred platinum coordination compounds include cisplatin, carboplatin, chloro (diethylenetriamine)-platinum (II) chloride; dichloro (ethylenediamine)-platinum (II); diamine (1, 1-cyclobutanedicarboxylato)- platinum (II) (carboplatin); spiroplatin ; iproplatin ; diamine (2-ethylmalonato)-platinum (II); (1,2-diaminocyclohexane) malonatoplatinum (II); (4-carboxyphthalo-1,2-diaminocyclohexane) platinum (II); (1,2-diaminocyclohexane)-(isocitrato) platinum (II); (1,2-diaminocyclohexane)-cis-(pyruvato) platinum (II); (1,2-diaminocyclohexane)-oxalato-platinum (II
  • Cisplatin is commercially available for example under the trade name Platinol from Bristol Myers Squibb Corporation as a powder for constitution with water, sterile saline or other suitable vehicle.
  • Other platinum coordination compounds and their pharmaceutical compositions are commercially available and/or can be prepared by conventional techniques.
  • Taxane compounds include for example Taxol from Bristol Myers Squibb, docetaxel (Taxotere) from Rhone-Poulenc Rorer and Carbazitaxel from Sanofi Pasteur.
  • Other taxane compounds may be prepared in conventional manner for example as described in EP 253738 , EP 253739 and WO 92/09589 or by processes analogous thereto.
  • Camptothecin compounds include irinotecan and topotecan.
  • Irinotecan is commercially available for example from Rhone-Poulenc Rorer under the trade name Campto and may be prepared for example as described in European patent specification No. 137145 or by processes analogous thereto.
  • Topotecan is commercially available for example from SmithKline Beecham under the trade name Hycamtin and may be prepared for example as described in European patent specification No. 321122 or by processes analogous thereto.
  • Other camptothecin compounds may be prepared in conventional manner for example by processes analogous to those described above for irinotecan and topotecan.
  • Anti-tumour vinca alkaloids include vinblastine, vincristine and vinorelbine referred to above.
  • Vinblastine is commercially available for example as the sulphate salt for injection from Eli Lilly and Co under the trade name Velban, and may be prepared for example as described in German patent specification No. 2124023 or by processes analogous thereto.
  • Vincristine is commercially available for example as the sulphate salt for injection from Eli Lilly and Co under the trade name Oncovin and may be prepared for example as described in the above German patent specification No. 2124023 or by processes analogous thereto.
  • Vinorelbine is commercially available for example as the tartrate salt for injection from Glaxo Wellcome under the trade name Navelbine and may be prepared for example as described in U. S. patent specification No. 4307100 , or by processes analogous thereto.
  • anti-tumour vinca alkaloids may be prepared in conventional manner for example by processes analogous to those described above for vinoblastine, vincristine and vinorelbine.
  • Anti-tumour nucleoside derivatives include 5-fluorouracil, gemcitabine and capecitabine referred to above.
  • 5-Fluorouracil is widely available commercially, and may be prepared for example as described in US Patent No. 2802005 .
  • Gemcitabine is commercially available for example from Eli Lilly under the trade name Gemzar and may be prepared for example as described in European patent specification No. 122707 or by processes analogous thereto.
  • Capecitabine is commercially available for example from Hoffman-La Roche under the trade name Xeloda and may be prepared for example as described in European patent specification No.
  • anti-tumour nucleoside derivatives may be prepared in conventional manner for example by processes analogous to those described above for capecitabine and gemcitabine.
  • Nitrogen mustard compounds include cyclophosphamide and chlorambucil.
  • Cyclophosphamide is commercially available for example from Bristol-Myers Squibb under the trade name Cytoxan and may be prepared for example as described in U. K. patent specification No. 1235022 or by processes analogous thereto.
  • Chlorambucil is commercially available for example from Glaxo Welcome under the trade name Leukeran and may be prepared for example as described in U. S. patent specification No. 3046301 , or by processes analogous thereto.
  • Preferred nitrosourea compounds for use in accordance with the invention include carmustine and lomustine referred to above.
  • Carmustine is commercially available for example from Bristol-Myers Squibb under the trade name BiCNU and may be prepared for example as described in European patent specification No. 902015 , or by processes analogous thereto.
  • Lomustine is commercially available for example from Bristol-Myers Squibb under the trade name CeeNU and may be prepared for example as described in U. S. patent specification No. 4377687 , or by processes analogous thereto.
  • Anti-tumour anthracycline derivatives include daunorubicin, doxorubicin and idarubicin referred to above.
  • Daunorubicin is commercially available for example as the hydrochloride salt from Bedford Laboratories under the trade name Cerubidine, and may be prepared for example as described in U. S. patent specification No. 4020270 , or by processes analogous thereto.
  • Doxorubicin is commercially available for example as the hydrochloride salt from Astra, and may be prepared for example as described in U. S. patent specification No. 3803124 or by processes analogous thereto.
  • Idarubicin is commercially available for example as the hydrochloride salt from Pharmacia & Upjohn under the trade name Idamycin, and may be prepared for example as described in U. S patent specification No.
  • anti-tumour anthracycline derivatives may be prepared in conventional manner for example by processes analogous to those described above for daunorubicin, doxorubicin and idarubicin.
  • Trastzumab is commercially available from Genentech under the trade name Herceptin and may be obtained as described in U. S. Patent specification No. 5821337 or PCT patent specifications WO 94/04679 and WO 92/22653 .
  • Anti-tumour anti-tumour podophyllotoxin derivatives include etoposide and teniposide.
  • Etoposide is commercially available for example from Bristol-Myers Squibb under the trade name VePesid, and may be prepared for example as described in European patent specification No. 111058 , or by processes analogous thereto.
  • Teniposide is commercially available for example from Bristol-Myers Squibb under the trade name Vumon and may be prepared for example as described in PCT patent specification No. WO 93/02094 , or by processes analogous thereto.
  • Other anti-tumour podophyllotoxin derivatives may be prepared in conventional manner for example by processes analogous to those described above for etoposide and teniposide.
  • anticancer drugs may e.g. be chosen from:
  • Example 1 production of raw NanoQuil F70 nanoparticles using PBS or Acetate buffer as reaction medium
  • NanoQuil F70 nanoparticles were produced three times in three successive days on 18, 19 and 20 July 2018. These three batches (Test-1, -2 and -3) of NanoQuil F70 were formulated in 5-50 mL Falcon tubes per batch (250 mL) and incubated for 1 hour at 70°C as implicated by the name NanoQuil F70 (formulation at 70°C).
  • the formulation protocol can be simplified as follows:
  • the mean particle sizes of the three formulations were 46.32 ⁇ 1.48nm, 40.07 ⁇ 0.98nm and 42.20 ⁇ 0.74nm, respectively, measured by Dynamic Light Scattering (DLS) analysis, see figure 5 . Below is shown a graphic summary of the DLS measurements.
  • DLS Dynamic Light Scattering
  • the hemolysis reduction rates for the three batches are rather similar: 31% for Test-1, 29% for Test-2 and 31% for Test-3 (below bar chart). This can be viewed as similar levels of side effect reduction by formulating Quil A into F70 were achieved, i.e. high degree of reproducibility in side effect reduction. It is observed, however, that all test batches induce hemolysis to a degree which is unacepptably high for a vaccine adjuvant.
  • NanoQuil F70 nanoparticles were produced using 4 different solvents: distilled water (D.W.), Saline solution (0.85% NaCl in D.W.), Acetate buffer (pH 4.6) and PBS (pH 7.4) according to the NanoQuil F70 protocol. Differences in particle size (hydrodynamic diameter) were observed by DLS in these formulations: NanoQuil F70 formulated in PBS gives the biggest size (about 42nm), followed by NanoQuil F70 formulated in Saline solution (about 35nm). NanoQuil F70 particles formulated in Acetate buffer (pH 4.6) and distilled water give particle sizes of around 25 and 24 nm respectively (see bar chart below).
  • F70 in Saline Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 41.99 1.186 24.92 0.114 23.87 0.7677 34.65 0.6031
  • the crude NanoQuil F70 product is purified by Size Exclusion Chromatography (SEC).
  • a volume of 13 mL of Sephacryl S300-HR (GE Healthcare Life Sciences) was placed in a PD-10 cartridge and equilibrated with PBS buffer or acetate buffer.
  • HPLC was used as a means to detect and quantify saponins and cholesterol in the S300-HR fractions.
  • Total saponin and cholesterol contents are expressed as signal integrals from the HPLC Charged Aerosol Detector (CAD) and plotted as a function of the S300-HR elution volume.
  • CAD Charged Aerosol Detector
  • the S300-HR chromatogram shows two peaks of saponins centered at 6-7 mL and 9-10 mL, and cholesterol is mostly associated with the peak at 6-7 mL, as expected with NanoQuil particles.
  • Nile Red (NR) fluorescence is quenched by polar molecules such as water, and therefore shows only weak fluorescence in aqueous environment.
  • Nile Red interacts with apolar molecules such as the triterpenoid core of saponins, or gets incorporated into micellar structures, its fluorescence is enhanced by orders of magnitude.
  • Nile Red is used as a tracer to monitor the presence of free QuilA saponins or NanoQuil particles in the S300-HR fractions.
  • the S300-HR chromatogram shows two peaks centered at fraction 6 mL, corresponding to NanoQuil particles (confirmed with TEM), and at 9 mL, corresponding to QuilA micelles.
  • NR fluorescence spectra for fractions 6 & 7 mL displayed the typical blue shift for nanoQuil (which indicates interaction with cholesterol) with emission maximum at 570 nm, whereas fractions 9 & 10 mL displayed the typical spectrum for QuilA micelles with an emission maximum at 620 nm.
  • NanoQuil F70 SEC fractionation A volume of 120 ⁇ L of each fraction from the NanoQuil F70 SEC fractionation is added to 480 ⁇ L of diluted fresh sheep blood treated with anticoagulant.
  • the dilution factor of NanoQuil F70 SEC fractions is 5-fold, whereas the sheep blood is diluted 12.5-fold in PBS buffer with EDTA 2 mM.
  • the most hemolytic S300-HR fractions i.e. 9 mL and 10 mL, are those containing free QuilA. Fractions 6 mL and 7 mL containing nanoQuil F70 do not show hemolytic effect in the conditions of the assay.
  • the raw nanoQuil F70 product on the other hand, does show hemolytic effect from 1 mg/mL equivalent QuilA and up.
  • a typical RP-HPLC chromatogram used for the quantitative analysis of the NanoQuil F70 nanoparticles is shown on figure 6 .
  • spiking with cholesterol from 0.1 mg/mL to 0.8 mg/mL yielded a linear response over this concentration range, which could be used for calibration and estimations of cholesterol contents in unknown fractions (SEC fractions of NanoQuil F70).
  • the fraction eluting at 6 mL from the 13 mL Sephacryl S300-HR cartridge and containing purified NanoQuil F70 was analyzed by HPLC. Integration of the signal between 20 mL and 32 mL (indicated by a horizontal grey bar in figure 6 ) was used to quantify the saponins in the fraction. Integration of the signal at 39 mL was used to quantify cholesterol.
  • NanoQuil F70 particles are eluted first, in fractions 5 mL to 8 mL where both QuilA saponin and cholesterol are found, whereas residual QuilA saponin with no cholesterol is eluted in later fractions from 9 mL to 12 mL.
  • This result is consistent with the way SEC fractionation is supposed to work, where the larger the particles the less they permeate into the polymeric mesh of the Sephacryl beads; therefore the earlier they elute from the column.
  • Nanoquil F70 particles have a hydrodynamic diameter of 20-50 nm (depending on reaction medium) whereas QuilA saponin micelles have a diameter of about 5 nm.
  • NanoQuil particles and QuilA saponin micelles are also consistent with the fractionation range for Sephacryl S300-HR.
  • a control experiment where only QuilA saponin was loaded onto the SEC column showed that QuilA saponin elutes in fractions 8-11 mL under the same conditions. This confirms that QuilA saponin found in fractions 5-8 mL, when NanoQuil F70 is injected ( Figure 7 ), is indeed associated with cholesterol.
  • TEM pictures of the material in fractions 5-8 mL confirmed the identity of NanoQuil F70 particles.
  • the SEC fractionation also shows that the amount of free QuilA saponin micelles (with no detectable cholesterol), in this batch, represents about 50% of the total amount of QuilA saponin in the raw NanoQuil F70 product. Finally, the initial ratio cholesterol/QuilA saponin measured in the raw NanoQuil F70 product was 3%, whereas it was found to be 13% in the combined SEC fractions from 5 ml to 8 mL.
  • NanoQuil F70 A volume of 1 mL of NanoQuil F70 at 4.2 mg/mL QuilA was loaded onto the Sephacryl S300-HR column and 1 mL fractions were collected for HPLC quantitative analyses. SEC fractions containing detectable amounts of QuilA, from 4 mL to 13 mL are shown. NanoQuil F70 and QuilA are shown as references.
  • the hemolytic activity of each SEC fraction was measured and compared with a QuilA saponin reference at 1 mg/mL as well as NanoQuil F70 raw product at 1 mg/mL QuilA.
  • the hemolytic activity of the different samples is presented as an Absorbance value at 540 nm which is directly correlated to the amount of hemoglobin released in the extracellular medium.
  • Figure 8 clearly shows that hemolytic activity was only observed for the SEC fractions 9-11 mL, where free QuilA micelles are essentially found. No hemolytic activity was recorded in fractions 5-8 mL, where purified NanoQuil was eluted (see Figure 7 for reference).
  • the aim of the study was to compare the vaccine adjuvant effect of the Nanoquil F-70 particles with the G3 particles described in WO2013051994 and WO2014163558 .
  • Results are shown graphically in figure 11 .
  • U937 cells are a model cell line originally isolated from the histiocytic lymphoma of a male patient and is characterized as a human acute myeloid leukemia (AML) cell line.
  • AML acute myeloid leukemia
  • Saponin can cause eye and respiratory irritation, and inflammation of the skin contact in some persons.
  • NanoQuil F70 particles Prepare serial dilution of NanoQuil F70 particles to concentrations from 1000 ⁇ g/ml down to 0.32 ⁇ g/ml (1:5 dilutions) in PBS pH 7,4.
  • the final concentration on cells will be from 100 ⁇ g/ml to 0.032 ⁇ g/ml on cells.
  • the QS-21 fraction of quillaja saponin formulated into nano particles has previously been shown to induce apoptosis in several cancer cell lines, as described in WO2013051994 and WO2014163558 .
  • the apoptotic effect of NanoQuil F70 particles tested herein on the monocytic cell line U937-1 measured by Alamar blue assay shows an EC50 of between 0.15 and 0.25 mg/ml after 3 days of incubation.
EP18213540.0A 2018-12-18 2018-12-18 Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin Withdrawn EP3669890A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP18213540.0A EP3669890A1 (fr) 2018-12-18 2018-12-18 Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
TW108145097A TW202038905A (zh) 2018-12-18 2019-12-10 具有疫苗佐劑效應之絲狀奈米粒子
CN201980083532.7A CN113365657A (zh) 2018-12-18 2019-12-16 具有疫苗佐剂效应的丝状纳米颗粒
AU2019409474A AU2019409474A1 (en) 2018-12-18 2019-12-16 Filamentous nanoparticles having vaccine adjuvant effect
JP2021534730A JP2022514276A (ja) 2018-12-18 2019-12-16 ワクチンアジュバント効果を有するフィラメント状ナノ粒子
BR112021011609-5A BR112021011609A2 (pt) 2018-12-18 2019-12-16 Nanopartículas filamentosas que têm efeito adjuvante de vacina
CA3123475A CA3123475A1 (fr) 2018-12-18 2019-12-16 Nanoparticules filamenteuses ayant un effet adjuvant de vaccin
EP19817767.7A EP3897713A1 (fr) 2018-12-18 2019-12-16 Nanoparticules filamenteuses ayant un effet adjuvant de vaccin
US17/312,796 US20230321227A1 (en) 2018-12-18 2019-12-16 Filamentous nanoparticles having vaccine adjuvant effect
KR1020217022094A KR20210105389A (ko) 2018-12-18 2019-12-16 백신 아주반트 효과를 갖는 필라멘트형 나노입자
PCT/EP2019/085444 WO2020127115A1 (fr) 2018-12-18 2019-12-16 Nanoparticules filamenteuses ayant un effet adjuvant de vaccin
ARP190103707A AR117712A1 (es) 2018-12-18 2019-12-17 Nanopartículas filamentosas que tienen efecto adyuvante de vacuna
ZA2021/03649A ZA202103649B (en) 2018-12-18 2021-05-27 Filamentous nanoparticles having vaccine adjuvant effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18213540.0A EP3669890A1 (fr) 2018-12-18 2018-12-18 Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin

Publications (1)

Publication Number Publication Date
EP3669890A1 true EP3669890A1 (fr) 2020-06-24

Family

ID=65003112

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18213540.0A Withdrawn EP3669890A1 (fr) 2018-12-18 2018-12-18 Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
EP19817767.7A Pending EP3897713A1 (fr) 2018-12-18 2019-12-16 Nanoparticules filamenteuses ayant un effet adjuvant de vaccin

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19817767.7A Pending EP3897713A1 (fr) 2018-12-18 2019-12-16 Nanoparticules filamenteuses ayant un effet adjuvant de vaccin

Country Status (12)

Country Link
US (1) US20230321227A1 (fr)
EP (2) EP3669890A1 (fr)
JP (1) JP2022514276A (fr)
KR (1) KR20210105389A (fr)
CN (1) CN113365657A (fr)
AR (1) AR117712A1 (fr)
AU (1) AU2019409474A1 (fr)
BR (1) BR112021011609A2 (fr)
CA (1) CA3123475A1 (fr)
TW (1) TW202038905A (fr)
WO (1) WO2020127115A1 (fr)
ZA (1) ZA202103649B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022073254A1 (fr) * 2020-10-06 2022-04-14 江苏艾洛特医药研究院有限公司 Procédé de préparation d'un vaccin anti-tumoral de taille nanométrique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230023348A (ko) 2021-08-10 2023-02-17 주식회사 엘지에너지솔루션 전극 조립체

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023A1 (de) 1970-05-27 1971-12-09 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin beziehungsweise von deren Salzen
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4046878A (en) 1974-06-12 1977-09-06 Societa' Farmaceutici Italia S.P.A. Daunomycin analogues, their preparation and use
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4377687A (en) 1978-10-19 1983-03-22 Stiftung Deutsches Krebsforschungszentrum Analogs of 1-(2-chloroethyl)-1-nitroso-3-(cycloheyl)-urea substituted by heterocyclic rings or alkyl radicals
EP0111058A1 (fr) 1982-11-26 1984-06-20 Nippon Kayaku Kabushiki Kaisha Procédé de préparation de 4'-déméthyl-épipodophyllotoxin-bêta-d-éthylidène-glucoside et dérivés acylés
EP0122707A1 (fr) 1983-03-10 1984-10-24 Eli Lilly And Company Agents antiviraux difluorés
EP0137145A1 (fr) 1983-07-14 1985-04-17 Kabushiki Kaisha Yakult Honsha Nouveaux dérivés de la camptothécine et procédé pour leur préparation
EP0253738A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0253739A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Procédé de préparation du taxol et du désacétyl-10 taxol
EP0321122A2 (fr) 1987-12-01 1989-06-21 Smithkline Beecham Corporation Analogues de la camptothécine solubles dans l'eau
WO1992009589A1 (fr) 1990-11-23 1992-06-11 Rhone-Poulenc Rorer S.A. Procede de preparation de derives du taxane, nouveaux derives obtenus et compositions pharmaceutiques qui les contiennent
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
WO1993002094A1 (fr) 1991-07-23 1993-02-04 Sicor Societa' Italiana Corticosteroidi S.P.A. Procede de preparation de demethylepypodophyllotoxine
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0698611A1 (fr) 1994-08-26 1996-02-28 F. Hoffmann-La Roche Ag Procédé de préparation de dérives de N-acyl-5-fluorocytidine
EP0902015A1 (fr) 1997-09-13 1999-03-17 Johnson Matthey Public Limited Company Procédé de la préparation des composés de nitrosourées
WO2013005199A1 (fr) 2011-07-07 2013-01-10 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Formulation facilitant une pollinisation ciblée des cultures de tournesols par les abeilles mellifères
WO2013051994A1 (fr) 2011-10-03 2013-04-11 Moreinx Ab Nanoparticules, leur procédé de préparation et leur utilisation comme support pour des molécules amphipatiques ou hydrophobes dans des domaines de la médecine, comprenant le traitement du cancer et des composés alimentaires
WO2014163558A1 (fr) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
RU2446822C2 (ru) * 2010-04-19 2012-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) Иммуностимулирующий комплекс, способ его получения и применение
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
CN105169386B (zh) * 2015-07-29 2018-06-19 浙江大学 一种新型通用型基质疫苗佐剂及其制备方法和用途

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023A1 (de) 1970-05-27 1971-12-09 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin beziehungsweise von deren Salzen
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4046878A (en) 1974-06-12 1977-09-06 Societa' Farmaceutici Italia S.P.A. Daunomycin analogues, their preparation and use
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4377687A (en) 1978-10-19 1983-03-22 Stiftung Deutsches Krebsforschungszentrum Analogs of 1-(2-chloroethyl)-1-nitroso-3-(cycloheyl)-urea substituted by heterocyclic rings or alkyl radicals
EP0111058A1 (fr) 1982-11-26 1984-06-20 Nippon Kayaku Kabushiki Kaisha Procédé de préparation de 4'-déméthyl-épipodophyllotoxin-bêta-d-éthylidène-glucoside et dérivés acylés
EP0122707A1 (fr) 1983-03-10 1984-10-24 Eli Lilly And Company Agents antiviraux difluorés
EP0137145A1 (fr) 1983-07-14 1985-04-17 Kabushiki Kaisha Yakult Honsha Nouveaux dérivés de la camptothécine et procédé pour leur préparation
EP0253738A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
EP0253739A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Procédé de préparation du taxol et du désacétyl-10 taxol
EP0321122A2 (fr) 1987-12-01 1989-06-21 Smithkline Beecham Corporation Analogues de la camptothécine solubles dans l'eau
WO1992009589A1 (fr) 1990-11-23 1992-06-11 Rhone-Poulenc Rorer S.A. Procede de preparation de derives du taxane, nouveaux derives obtenus et compositions pharmaceutiques qui les contiennent
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993002094A1 (fr) 1991-07-23 1993-02-04 Sicor Societa' Italiana Corticosteroidi S.P.A. Procede de preparation de demethylepypodophyllotoxine
EP0698611A1 (fr) 1994-08-26 1996-02-28 F. Hoffmann-La Roche Ag Procédé de préparation de dérives de N-acyl-5-fluorocytidine
EP0902015A1 (fr) 1997-09-13 1999-03-17 Johnson Matthey Public Limited Company Procédé de la préparation des composés de nitrosourées
WO2013005199A1 (fr) 2011-07-07 2013-01-10 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Formulation facilitant une pollinisation ciblée des cultures de tournesols par les abeilles mellifères
WO2013051994A1 (fr) 2011-10-03 2013-04-11 Moreinx Ab Nanoparticules, leur procédé de préparation et leur utilisation comme support pour des molécules amphipatiques ou hydrophobes dans des domaines de la médecine, comprenant le traitement du cancer et des composés alimentaires
WO2014163558A1 (fr) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
B. KARAGOZ ET AL.: "Polymerization-Induced Self-Assembly (PISA) - control over the morphology of nanoparticles for drug delivery applications", POLYM. CHEM., 2014
CAROLIN DE GROOT ET AL.: "Novel colloidal microstructures of Beta-Escin and the liposomal components Cholesterol and DPPC", PLANTA MEDICA, vol. 84, no. 16, November 2018 (2018-11-01), pages 1219 - 1227, XP002791912, DOI: 10.1055/A-0624-2706 *
ELIZABETH HINDE ET AL.: "Pair correlation microscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release", NATURE NANOTECHNOLOGY, vol. 12, 2017, pages 81 - 89
KENSIL, C. R. ET AL.: "Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex", THE JOURNAL OF IMMUNOLOGY, vol. 146, no. 2, 1991, pages 431 - 437
LENDEMANS DIRK G ET AL: "Immuno-stimulating complexes prepared by ethanol injection.", THE JOURNAL OF PHARMACY AND PHARMACOLOGY JUN 2005, vol. 57, no. 6, June 2005 (2005-06-01), pages 729 - 733, XP002791911, ISSN: 0022-3573 *
MAZEYKA A N ET AL: "Elaboration of Immune Stimulating Lipid-Saponin Subunit Antigen Carrier Based on Glycolipid Monogalactosyldiacylglycerol from Sea Macrophytes and Triterpene Glycosides from Cucumaria japonica", BIOFIZIKA, vol. 58, no. 5, September 2013 (2013-09-01), pages 616 - 623, XP002791913, DOI: 10.1134/S0006350913050084 *
ODA, K. ET AL.: "Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants", BIOLOGICAL CHEMISTRY, vol. 381, no. 1, 2000, pages 67 - 74, XP003005996, DOI: doi:10.1515/BC.2000.009
S G VERZA ET AL: "Micellar aggregates of saponins from Chenopodium quinoa: characterization by dynamic light scattering and transmission electron microscopy", DIE PHARMAZIE, 1 April 2012 (2012-04-01), Germany, pages 288 - 292, XP055203268, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/22570933> DOI: 10.1691/ph.2012.1102 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022073254A1 (fr) * 2020-10-06 2022-04-14 江苏艾洛特医药研究院有限公司 Procédé de préparation d'un vaccin anti-tumoral de taille nanométrique

Also Published As

Publication number Publication date
TW202038905A (zh) 2020-11-01
WO2020127115A1 (fr) 2020-06-25
AR117712A1 (es) 2021-08-25
JP2022514276A (ja) 2022-02-10
CN113365657A (zh) 2021-09-07
BR112021011609A2 (pt) 2021-08-31
CA3123475A1 (fr) 2020-06-25
ZA202103649B (en) 2022-09-28
KR20210105389A (ko) 2021-08-26
US20230321227A1 (en) 2023-10-12
EP3897713A1 (fr) 2021-10-27
AU2019409474A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CN110522919B (zh) 甘露糖受体靶向的组合物、药物及其制备方法和应用
Zhang et al. The chemotherapeutic potential of PEG-b-PLGA copolymer micelles that combine chloroquine as autophagy inhibitor and docetaxel as an anti-cancer drug
US10100078B2 (en) Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US20180104330A1 (en) Nanoparticles, Composed of Sterol and Saponin From Quillaja Saponaria Molina Process for Preparation and Use Thereof as Carrier for Amphipatic of Hydrophobic Molecules in Fields of Medicine Including Cancer Treatment and Food Related Compounds
CN108420793A (zh) 一种空白混合胶束及其制备方法和应用
JP2018528269A (ja) ギンセノシドを膜材料として有するリポソームならびにその調製および使用
Yue et al. Molecular structure matters: PEG-b-PLA nanoparticles with hydrophilicity and deformability demonstrate their advantages for high-performance delivery of anti-cancer drugs
CN105126115A (zh) 二氧化硅纳米颗粒及其用于疫苗接种的用途
US20170136127A1 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
Shi et al. Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer
CN105853403B (zh) 一种紫杉醇棕榈酸酯脂质体及其制备方法
CN113797343A (zh) 使用辅酶q10联合疗法治疗癌症
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
US20230321227A1 (en) Filamentous nanoparticles having vaccine adjuvant effect
Almoshari Development, therapeutic evaluation and theranostic applications of cubosomes on cancers: An updated review
Zhao et al. A new tandem peptide modified liposomal doxorubicin for tumor “ecological therapy”
EA018636B1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
Wang et al. “Layer peeling” co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy
Raza et al. Engineered tumor microvesicles modified by SP94 peptide for arsenic trioxide targeting drug delivery in liver cancer therapy
Yin et al. Fructose-coated Ångstrom silver prevents sepsis by killing bacteria and attenuating bacterial toxin-induced injuries
CN108853056B (zh) 一种叶酸靶向修饰共载盐酸阿霉素和藤黄酸纳米结构脂质载体制剂及其制备方法
CN107982214B (zh) 兽用恩诺沙星固体脂质纳米混悬液及其制备方法
Fan et al. Polysialic acid self-assembled nanocomplexes for neutrophil-based immunotherapy to suppress lung metastasis of breast cancer
Niemelä Nanoparticles as Targeting System for Cancer Treatment: From idea towards reality
Zhu et al. Injectable Nanocomposite Immune Hydrogel Dressings: Prevention of Tumor Recurrence and Anti‐Infection after Melanoma Resection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210112